Fig. 3: PT regression and necrosis and EFS in the path-evaluable patient population. | Nature Medicine

Fig. 3: PT regression and necrosis and EFS in the path-evaluable patient population.

From: Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Fig. 3

a,b, Difference in %regression-PT (a) and %necrosis-PT (b) between paired pretreatment and on-treatment tumor tissue specimens from individual patients (n = 47). c, Kaplan–Meier curves showing EFS by %necrosis-PT (0% versus >0%) in on-treatment specimens for all path-evaluable patients treated with nivolumab plus chemotherapy and chemotherapy.

Back to article page